Real-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation

被引：0

作者：

Tanaka, K. ^{[1
]}

Inui, N. ^{[2
]}

Asada, K. ^{[3
]}

Abe, T. ^{[4
]}

Hataji, O. ^{[5
]}

Hayai, S. ^{[6
]}

Ito, K. ^{[5
]}

Imaizumi, K. ^{[7
]}

Kimura, T. ^{[8
]}

Kubo, A. ^{[9
]}

Kunii, E. ^{[10
]}

Murotani, K. ^{[11
]}

Okuno, M. ^{[12
]}

Oya, Y. ^{[13
]}

Shindoh, J. ^{[4
]}

Taniguchi, H. ^{[14
]}

Tsuda, T. ^{[14
]}

Yamaguchi, T. ^{[13
]}

Hida, T. ^{[13
]}

Suda, T. ^{[1
]}

机构：

[1] Hamamatsu Univ Sch Med, Internal Med 2, Hamamatsu, Shizuoka, Japan

[2] Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapuet, Hamamatsu, Shizuoka, Japan

[3] Shizuoka Prefectural Gen Hosp, Dept Resp, Shizuoka, Japan

[4] Ogaki Municipal Hosp, Dept Resp Med, Ogaki, Japan

[5] Matsusaka City Hosp, Resp Ctr, Matsusaka, Japan

[6] Chutoen Gen Med Ctr, Dept Resp Med, Kakegawa, Japan

[7] Fujita Hlth Univ, Dept Resp Med, Toyoake, Aichi, Japan

[8] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Japan

[9] Aichi Med Univ, Div Resp Med & Allergol, Nagakute, Aichi, Japan

[10] Nagoya City West Med Ctr, Dept Resp Med, Resp Tract Oncol Ctr, Nagoya, Aichi, Japan

[11] Kurume Univ, Grad Sch Med, Biostat Ctr, Kurume, Fukuoka, Japan

[12] Aichi Hosp, Aichi Canc Ctr, Dept Resp Med, Okazaki, Aichi, Japan

[13] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan

[14] Toyama Prefectural Cent Hosp, Dept Internal Med, Toyama, Japan

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

521P

引用

页数：1

共 50 条

[1] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
Luo, Yung-Hung
Liu, Han
Wampfler, Jason A.
Tazelaar, Henry D.
Li, Yalun
Peikert, Tobias
Liu, Dan
Leventakos, Konstantinos
Chen, Yuh-Min
Yang, Yanan
Chiou, Shih-Hwa
Yang, Ping
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2099 - 2114
[2] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
Yung-Hung Luo
Han Liu
Jason A. Wampfler
Henry D. Tazelaar
Yalun Li
Tobias Peikert
Dan Liu
Konstantinos Leventakos
Yuh-Min Chen
Yanan Yang
Shih-Hwa Chiou
Ping Yang
Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2099 - 2114
[3] Characterization of T790M According to Primary EGFR Mutation in Post EGFR-TKI Progression NSCLC in Brazil
Ferreira, C.
Zalis, M.
Custodio, M.
Montenegro, G.
Zukin, M.
Mathias, C.
Haddad, C.
Mascarenhas, E.
Araujo, L.
Montella, T.
Da Silva, B.
Bustamante, C.
Muras, A.
Reis, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S158 - S158
[4] T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
Ren, Shengxiang
Li, Wei
Li, Aiwu
Chen, Xiaoxia
Gao, Guanghui
He, Yayi
Li, Xuefei
Zhou, Caicun
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1084 - S1084
[5] Detection of T790M mutation in EGFR gene, an EGFR-TKI resistant mutation, in tumor samples unexposed to EGFR TKIs
Koba, Hayato
Kimura, Hideharu
Nishikawa, Shingo
Yoneda, Taro
Sone, Takashi
Kasahara, Kazuo
CANCER RESEARCH, 2016, 76
[6] EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis
Liu, Sangtian
Liang, Wenhua
He, Jianxing
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] Noninvasive detection of acquired T790M mutation in NSCLC patients treated with EGFR-TKI using digital PCR of plasma
Ishii, Hidenobu
Azuma, Koichi
Sakai, Kazuko
Tokito, Takaaki
Yamada, Kazuhiko
Nishio, Kazuto
Hoshibo, Tomoaki
ANNALS OF ONCOLOGY, 2015, 26 : 138 - 138
[8] T790M mutation and c-MET amplification might be correlated to TTP of EGFR-TKI in NSCLC
Wu, Y.
Mok, T. S.
Chen, H.
Zhang, X.
Guo, A.
Jaenne, P. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[9] De Novo Emergence of Isolated CNS T790M Mutation as a Mechanism of Resistance to First Generation EGFR-TKI Erlotinib
Al Rabadi, L.
Tolba, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1048 - S1048
[10] Osimertinib in previously EGFR-TKI treated non-small cell lung cancer (NSCLC) patients without T790M mutation: Real-world evidence.
Luo, Yung-Hung
Liu, Han
Wampfler, Jason A.
Tazelaar, Henry D.
Li, Yalun
Peikert, Tobias
Liu, Dan
Leventakos, Konstantinos
Chen, Yuh-Min
Yang, Yanan
Chiou, Shih-Hwa
Yang, Ping
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →